The Enforcement Directorate, which arrested Chief Minister Arvind Kejriwal on March 21 in the Delhi excise policy case, told the Supreme Court Friday that it has found “personal, direct chats” between ...

Imdelltra activates a patient’s T cells to attack Delta-like ligand 3 (DLL3)-expressing tumors. While SCLC cases comprise just 15% of lung cancers, they're typically deadlier and more aggressive ...

Amgen AMGN announced that the FDA has granted accelerated approval to tarlatamab for pre-treated advanced small cell lung cancer (ES-SCLC). Tarlatamab is a delta-like ligand 3 targeting Bispecific ...

Imdelltra is the first and only DLL3-targeting Bispecific T-cell Engager therapy that activates the patient’s T cells to attack DLL3-expressing tumor cells. The FDA accelerated approval of ...

This DLL3-targeting therapy in ES-SCLC comprises a transformative option demonstrating long-lasting responses in pretreated patients,” said Jay Bradner, M.D., executive vice president, Research and ...

3 "The FDA's approval of Imdelltra marks a pivotal moment for patients battling ES-SCLC. This DLL3-targeting therapy in ES-SCLC comprises a transformative option demonstrating long-lasting ...

A Delta-like ligand 3 (DLL3)-targeting bispecific T-cell engager (BiTE) therapy, IMDELLTRA is indicated for ES-SCLC patients who have experienced disease progression on or following platinum-based ...

A group of billionaires privately pressed New York City Mayor Eric Adams to break up campus protests at Columbia University in April, according to The Washington Post. The newspaper’s report is based ...

During the call, some attendees discussed making political donations to Adams, as well as how the chat group’s members could pressure Columbia’s president and trustees to permit the mayor to ...

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median ...